LEBER HEREDITARY OPTIC NEUROPATHY

Leber Hereditary Optic Neuropathy — the most common inherited optic neuropathy, where idebenone therapy can preserve or restore vision when initiated early after symptom onset, but only with confirmed molecular diagnosis.

Whole genome sequencing reads the complete mitochondrial genome — identifying the three primary LHON variants (m.11778G>A, m.3460G>A, m.14484T>C) that account for 95% of cases and determine visual prognosis.

MT-ND4
MT-ND1
MT-ND6

About this condition

Leber Hereditary Optic Neuropathy

Leber hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial optic neuropathy caused by pathogenic variants in the mitochondrial genome (mtDNA). Three primary variants account for approximately 95% of all LHON cases: m.11778G>A (MT-ND4, ~70% of cases), m.3460G>A (MT-ND1, ~13%), and m.14484T>C (MT-ND6, ~14%). These variants impair mitochondrial complex I function, causing selective degeneration of retinal ganglion cells — the neurons whose axons form the optic nerve. LHON affects approximately 1 in 25,000-50,000 and shows marked male predominance (~5:1 male-to-female ratio), suggesting modifying nuclear or hormonal factors.

LHON typically presents in young adults (median onset age 20-30 years) with acute or subacute painless central vision loss, initially unilateral then rapidly progressing to bilateral involvement within weeks to months. Vision deteriorates to legal blindness (visual acuity typically 20/200 to counting fingers) with dense central scotoma. The acute phase shows optic disc pseudoedema and peripapillary telangiectatic microangiopathy on fundoscopy. Spontaneous partial visual recovery occurs in approximately 20-25% of patients with m.11778G>A and up to 50-65% of patients with m.14484T>C — making genotype the strongest predictor of visual prognosis.

Idebenone (Raxone/Catena), a synthetic analog of coenzyme Q10, was approved by the EMA in 2015 for treatment of LHON. Idebenone bypasses the complex I defect, shuttling electrons directly to complex III. Clinical trials demonstrated that idebenone preserves or improves visual acuity when initiated early after symptom onset — before retinal ganglion cell loss becomes irreversible. The treatment window is narrow: benefit is greatest when idebenone is started within the first year of vision loss, particularly in the first affected eye (before the second eye becomes involved). Gene therapy (lenadogene nolparvovec, intravitreal AAV delivery of MT-ND4) is approved in several countries for m.11778G>A LHON.

The m.14484T>C variant has the best spontaneous recovery rate (~50-65%) while m.11778G>A has the worst (~20-25%). Genotype is the strongest predictor of visual prognosis — directly affecting treatment urgency and counseling.

Gene locus: MT-ND4 (m.11778G>A), MT-ND1 (m.3460G>A), MT-ND6 (m.14484T>C) — mitochondrial genome

LHON is mitochondrial, maternally inherited, and variably penetrant. Whole genome sequencing reads both nuclear and mitochondrial genomes — identifying the LHON variant and assessing heteroplasmy levels that influence penetrance.

Idebenone and gene therapy require rapid molecular diagnosis — the treatment window closes as retinal ganglion cells die

Idebenone produces the best visual outcomes when started within months of symptom onset, before retinal ganglion cell degeneration becomes irreversible. Gene therapy (lenadogene nolparvovec) is specifically approved for m.11778G>A LHON and requires molecular confirmation for prescribing. Any young adult presenting with acute painless bilateral sequential vision loss should have immediate mtDNA evaluation for LHON — delays in molecular diagnosis directly translate to treatment delays that reduce the chance of visual recovery.

Maternal family members carry the same mtDNA variant — presymptomatic identification enables lifestyle modification and early treatment readiness

All maternal relatives of a confirmed LHON patient carry the same mtDNA variant, though penetrance varies widely (approximately 50% of males and 15% of females become symptomatic). Presymptomatic carriers benefit from lifestyle counseling — tobacco smoking and heavy alcohol use are established triggers for LHON conversion. Additionally, presymptomatic carriers can be educated about early symptoms, enabling immediate idebenone initiation at the first sign of vision change rather than after delayed clinical evaluation.

Leber Hereditary Optic Neuropathy — the most common inherited optic neuropathy, where idebenone therapy can preserve or restore vision when initiated early after symptom onset, but only with confirmed molecular diagnosis.

Leber Hereditary Optic Neuropathy

LHON is mitochondrial, maternally inherited, and variably penetrant. Whole genome sequencing reads both nuclear and mitochondrial genomes — identifying the LHON variant and assessing heteroplasmy levels that influence penetrance.

Idebenone and gene therapy require rapid molecular diagnosis — the treatment window closes as retinal ganglion cells die

Maternal family members carry the same mtDNA variant — presymptomatic identification enables lifestyle modification and early treatment readiness

Others in Neurological

One test. A lifetime of answers.